Bio-Rad Laboratories (BIO-B) Receivables - Net (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Receivables - Net data on file, last reported at $426.2 million in Q1 2026.

• Quarterly Receivables - Net changed 0.35% year-over-year to $426.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $426.2 million (changed 0.35% YoY) and the FY2025 annual result came in at $460.6 million, up 1.79% from the prior year.
• Receivables - Net eased to $426.2 million in Q1 2026 per BIO-B's latest filing, from $460.6 million in the prior quarter.
• Across five years, Receivables - Net topped out at $498.3 million in Q1 2023 and bottomed at $424.7 million in Q1 2025.
• The 5-year median for Receivables - Net is $460.6 million (2025), against an average of $460.5 million.
• The widest annual swing landed in 2022, when Receivables - Net increased 16.79%; it then dropped 10.73% in 2024.
• Tracing BIO-B's Receivables - Net over 5 years: stood at $494.6 million in 2022, then declined by 1.14% to $489.0 million in 2023, then decreased by 7.46% to $452.5 million in 2024, then gained by 1.79% to $460.6 million in 2025, then fell by 7.47% to $426.2 million in 2026.
• Per Business Quant, the three latest BIO-B Receivables - Net figures stand at $426.2 million (Q1 2026), $460.6 million (Q4 2025), and $464.7 million (Q3 2025).

Peer Comparison